Exane Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Exane Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-82,881	Closed	-$8.04M	–	121
2018 Q3	$8.04M	Sell	82,881 -32,305	-28%	-$3.22M	2.52%	15
2018 Q2	$10.9M	Sell	115,186 -17,881	-13%	-$1.57M	4.7%	6
2018 Q1	$10.8M	Sell	133,067 -28,122	-17%	-$2.41M	3.24%	11
2017 Q4	$14.4M	Buy	161,189 +40,989	+34%	+$3.56M	4.46%	10
2017 Q3	$11.2M	Buy	+120,200	New	+$10.6M	2.19%	18
2017 Q1	–	Sell	-101,548	Closed	-$8.41M	–	39
2016 Q4	$8.41M	Sell	101,548 -28,990	-22%	-$2.49M	2.77%	17
2016 Q3	$12.1M	Sell	130,538 -32,684	-20%	-$3.08M	3.79%	10
2016 Q2	$12.7M	Buy	163,222 +17,402	+12%	+$1.48M	4.93%	8
2016 Q1	$12M	Buy	+145,820	New	+$11.9M	6.26%	5

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Exane Asset Management's BMRN Position: Q4 2018 in Review

Exane Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2018, closing a stake of 82,881 shares — an estimated $8.04M sold.

Exane Asset Management first reported a position in BMRN in Q1 2016 and held it in 9 quarters. The position peaked at $14.4M in Q4 2017. 473 funds tracked by Wall St. Rank hold BMRN as of Q4 2018.

Exane Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Exane Asset Management sold 82,881 BioMarin Pharmaceuticals shares in Q4 2018, an estimated $8.04M.
Exane Asset Management first reported a position in BioMarin Pharmaceuticals in Q1 2016 and held it in 9 quarters.
Exane Asset Management's BioMarin Pharmaceuticals position peaked at $14.4M in Q4 2017.
473 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2018.

Based on Exane Asset Management's 13F filing for Q4 2018, filed 5 Feb 2019.